Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors
| Autor: | Daniela M. Zisterer, Nicola Relitti, Giuseppe Campiani, Margherita Brindisi, Sandra Gemma, Stefania Butini, A Prasanth Saraswati |
|---|---|
| Přispěvatelé: | Saraswati, A. P., Relitti, N., Brindisi, M., Gemma, S., Zisterer, D., Butini, S., Campiani, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Telomerase Antineoplastic Agents Biology 03 medical and health sciences 0302 clinical medicine Neoplasms Drug Discovery medicine Humans Enzyme Inhibitors Pharmacology Cancer RNA Telomere medicine.disease Reverse transcriptase 3. Good health 030104 developmental biology Cell culture 030220 oncology & carcinogenesis Cancer cell Cancer research Stem cell |
| Zdroj: | Drug Discovery Today |
| Popis: | Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3' end of the chromosomes. 85-90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer cell development. However, in normal cells, telomerase activity is almost always absent except in germ cells and stem cells. This differential expression has been exploited to develop highly specific and potent cancer therapeutics. In this review, we outline recent advances in the development of telomerase inhibitors as anticancer agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|